J&amp;J Partners with Emergent to Manufacture its  AD26 Covid-19 Vaccine

Emergent BioSolutions has announced a 5-year manufacturing agreement with Janssen Pharma, of Johnson &amp; Johnson
$JNJ $EBS $NVAX $MRNA $INO #vaccine #investment #stockmarket #jpmorgan https://t.co/nQhBni2G5r https://t.co/jhd2JOUqKJ